NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
神經博製藥和其他兩隻低價股票的內部人員正在購買
The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週二下跌約300點。當內部人士買入或賣出股票時，這表明他們對公司前景的信心或關注。對於對小盤股感興趣的投資者和交易者，可以考慮這一因素作爲總體投資或交易決策的因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。
Nanophase Technologies
Nanophase Technologies
- The Trade: Nanophase Technologies Corporation (NASDAQ:NANX) Chief Operating Officer Kevin Cureton bought a total of 11,675 shares at an average price of $1.49. To acquire these shares, it cost around $17,414.
- What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.
- What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.
- 交易：Nanophase Technologies Corporation（NASDAQ：NANX）首席運營官Kevin Cureton以平均價格1.49美元購買了總共11,675股。要獲得這些股票，花費約17,414美元。
- 近況：4月23日，Nanophase Technologies宣佈了2024年3月31日結束的第一季度的財務業績。
- Nanophase Technologies Corp專注於生產工程納米材料解決方案和更大型的次微米材料，例如個人護理防曬霜、建築塗料、工業塗料應用、耐磨添加劑、塑料添加劑、醫療診斷和能源等。
Nuvation Bio
Nuvation Bio
- The Trade: Nuvation Bio Inc. (NYSE:NUVB) Director Xiangmin Cui acquired a total of 500,000 shares at an average price of $2.98. To acquire these shares, it cost around $1.5 million.
- What's Happening: On June 3, HC Wainwright & Co. analyst Robert Burns reiterated Nuvation Bio with a Buy and maintained a price target of $8.
- What Nuvation Bio Does: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
- 交易：Nuvation Bio Inc.（NYSE：NUVB）董事Xiangmin Cui以平均價格2.98美元購買了總共500,000股。要獲得這些股票，花費約1.5百萬美元。
- 最新情況：6月3日，HC Wainwright＆Co.分析師Robert Burns重申了對Nuvation Bio的買入評級，並維持了8美元的目標價。
- Nuvation Bio的業務：Nuvation Bio Inc是一家生物技術公司，通過開發不同和新穎的治療候選者，解決腫瘤領域的未滿足需求。
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals
- The Trade: NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) President and CEO Faheem Hasnain acquired a total of 2,544,530 shares at an average price of $3.13. The insider spent around $7.97 million to buy those shares.
- What's Happening: On June 25, NeuroBo Pharmaceuticals announced the closing of up to $70 million concurrent private placement and registered direct offering priced at-the-market under Nasdaq rules.
- What NeuroBo Pharmaceuticals Does: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
- 交易：NeuroBo Pharmaceuticals，Inc.（NASDAQ：NRBO）總裁兼首席執行官Faheem Hasnain以平均價格3.13美元購買了總共2,544,530股。這位內部人士花費大約797萬美元購買這些股票。
- 最新情況：6月25日，NeuroBo Pharmaceuticals宣佈根據納斯達克規則以市價定價的方式完成高達7000萬美元的同時私募和註冊直接發行。
- NeuroBo Pharmaceuticals的業務：NeuroBo Pharmaceuticals Inc是一家臨床階段的生物技術公司，主要專注於開發和商業化用於治療代謝和心血管疾病的新型藥物。
Read More: Top 3 Materials Stocks That May Explode In Q2
了解更多：可能在第二季度爆發的前三家材料股
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。